Navigo card

FDB Vela™ Leader to Share Vision for Vastly Reducing Fill Times for Specialty Drug ePrescribing at NCPDP Annual Conference

Retrieved on: 
Thursday, May 4, 2023
Well, Pharmacy technician, Electronic prescribing, Doctor of Pharmacy, Pharmacy, The Westin Kierland Resort & Spa, Convention, Drug utilization review, Innovation, First Databank, MBA, FDB, Bigler, Accreditation Council for Pharmacy Education, Pharmacist, Patel, DUR, NCPDP, ACPE, National Primate Research Exhibition Hall, Patient, Navigo card, Great race, Frustration, Accreditation, Accreditation Council, HL7, Health, Conference, CPE, Safety, Meeting, Nursing

SOUTH SAN FRANCISCO, Calif., May 4, 2023 /PRNewswire/ -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise decisions, announced today that Lathe Bigler, vice president of clinical network services for FDB Vela™, will share insights at the NCPDP 2023 Annual Technology & Business Conference on how prescribers can quickly and simply electronically prescribe specialty medications based on new standards, processes, and tools to reduce fill time from weeks to hours (in many cases) and give patients greater access to care.

Key Points: 
  • Recently celebrating its first anniversary, FDB Vela empowers innovation, reduces barriers to participation, and increases the cost-effectiveness of electronic prescribing.
  • These advances help close gaps in care in the specialty medication process while improving prescriber efficiency, increasing patient adherence, and reducing frustration for all involved.
  • Bigler continued, "The hurdles involved in the current state of specialty drug prescribing cause widespread dissatisfaction among stakeholders.
  • Also speaking at the NCPDP 2023 Annual Technology & Business Conference will be Chirag Patel, PharmD, MBA, senior product manager for FDB.

Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), Protein, Annual report, Securities Exchange Act of 1934, CEO, Leadership, U.S. Securities and Exchange Commission, Ecolab, Partnership, General manager, Chromatography, GLOBE, Ligand, Acceleration, Repligen Corporation Award in Chemistry of Biological Processes, Securities Act of 1933, Navigo card, Repligen, VP, Technology, NASDAQ, Process analytical technology, Filtration, NGL, Senior, Solution, Mab, Fine chemical

WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (Purolite), for the development and manufacturing of affinity ligands focused on monoclonal antibodies (mAb) and antibody fragments.

Key Points: 
  • WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company (Purolite), for the development and manufacturing of affinity ligands focused on monoclonal antibodies (mAb) and antibody fragments.
  • Repligen entered into an exclusive agreement with Purolite in 2018 for the development and supply of NGL-Impact Protein A ligands.
  • This agreement extends our exclusive partnership to 2032 and broadens the scope of the partnership to now include ligands targeting mAb fragments.
  • Hayley Crowe, Senior VP and General Manager of Purolite, said, Purolite and Repligen have for years worked together to bring industry-best protein A ligands and chromatography resins into the bioprocessing market.

FDB Launches FDB Navigo™ -- a Smarter, Holistic Approach to Optimize Clinical Guidance for Retail Pharmacy

Retrieved on: 
Thursday, August 25, 2022
Patient safety, Doctor of Pharmacy, First Databank, COVID-19, Pharmacist, Patient, Safety, Navigo card, SAN, Allergy, Time, YouTube, Solution, Precision medicine, Pharmacy, Topical steroid withdrawal, Hearst, MHK, LinkedIn, Prescription, Workflow, Hospital, HIV, Drug, Conference, FDB, Twitter, MCG, Risk, Health, Review, Medicine, Pharmaceutical industry, Healthcare

SAN FRANCISCO, Aug. 25, 2022 /PRNewswire/ -- FDB (First Databank, Inc.), the leading provider of drug knowledge that helps healthcare professionals make precise decisions, announced today the launch of FDB NavigoTM, a cloud-based solution that introduces a smarter, holistic approach to clinical guidance for medication safety risks. FDB Navigo provides retail pharmacists with targeted, consolidated and actionable clinical guidance at the most optimal time in their workflow.

Key Points: 
  • FDB Navigo provides retail pharmacists with targeted, consolidated and actionable clinical guidance at the most optimal time in their workflow.
  • FDB developed FDB Navigo over the past three years in collaboration with a major retail pharmacy chain.
  • Specifically, FDB Navigo provides actionable guidance to the pharmacist based on the most important risks to the patient as reflected in the patient's clinical record in the pharmacy's system.
  • Furthermore, FDB Navigo consolidates the appropriate information across all major clinical domainsincluding drug interactions, allergies, precautions and dosing informationto eliminate the current "siloed" approach in which retail pharmacists need to consider alerts within each clinical domain.

Repligen and Navigo GmbH Announce Launch of Industry-First Protein A Ligand for Purification of pH Sensitive Antibodies

Retrieved on: 
Thursday, September 9, 2021

Named NGL-Impact A Hi pH, the new ligand is the first to address antibody aggregation in low pH elution buffers.

Key Points: 
  • Named NGL-Impact A Hi pH, the new ligand is the first to address antibody aggregation in low pH elution buffers.
  • While developed specifically to address pH sensitive antibodies and Fc-fusion proteins, NGL-Impact A Hi pH ligand demonstrates high performance for all antibodies, and can be considered for platform use due to its broad pH operating range.
  • The introduction of a high pH, high performing ligand into the market represents a potential real cost- and time savings for developers of pH sensitive antibodies and Fc-fusion proteins.
  • We believe the performance enabled by this ligand will prove very attractive in the market, for purification of all antibodies and Fc containing proteins.

Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 Vaccines

Retrieved on: 
Thursday, October 1, 2020
Natural sciences, Physical sciences, Branches of biology, Proteins, Affinity, Navigo card, COVID-19 vaccine, Downstream processing, Chromatography, Ligand

The affinity resin aims to provide end users with a rapid, high purity capture step, decreasing processing time and potentially improving overall yield in the manufacturing of critical COVID-19 vaccines.

Key Points: 
  • The affinity resin aims to provide end users with a rapid, high purity capture step, decreasing processing time and potentially improving overall yield in the manufacturing of critical COVID-19 vaccines.
  • Repligen anticipates that the final resin product will be commercially available in early 2021.
  • Navigo Proteins is a premier protein engineering company, specialized in creating novel affinity ligands for PRECISION CAPTURING and PRECISION TARGETING.
  • Navigo works with renowned partners to convert its affinity ligands into ready-to-use, GMP-compliant affinity resins for commercial downstream processing.

ITS Navigo® Announces Patent Pending Touchless Technology for Safer Public Reopening

Retrieved on: 
Monday, August 17, 2020
Transport in Île-de-France, Navigo card, Contactless, Visitor management

CROFTON, Md.and NEW YORK, Aug. 17, 2020 /PRNewswire/ --Interactive Touchscreen Solutions, Inc., developer of Navigo software technology, announces a patent pending for their touchless software technology.

Key Points: 
  • CROFTON, Md.and NEW YORK, Aug. 17, 2020 /PRNewswire/ --Interactive Touchscreen Solutions, Inc., developer of Navigo software technology, announces a patent pending for their touchless software technology.
  • Navigo provides a fully contactless solution to validate and grant access digitally for touchless access to secured entryways of buildings.
  • The capabilities Navigo provides streamline and enhance security and access control, and, with its touchless functionality, enables a healthier environment for occupancy.
  • Navigo patent pending touchless technology is a fully touchless visitor management system (VMS) solution that virtualizes the check-in, credentialing, and access badging procedures with mobile technology.